Pharmacy Question for the Week of July 2, 2018

Pharmacy Compliance Question of the Week

Question:

Are there any new pass-through drugs for the upcoming quarter?

Answer:

The Centers for Medicare & Medicaid Services (CMS) have granted outpatient prospective payment system (OPPS) pass-through status, effective July 1, 2018 the following drugs and biological:

C9030 Injection, copanlisib, 1 mg
C9031 Lutetium Lu 177, dotatate, therapeutic, 1 mCi
C9032 Injection, voretigene neparvovec-rzyl, 1 billion vector genome
Q9991 Injection, buprenorphine extendedrelease (Sublocade), less than or equal to 100 mg
Q9992 Injection, buprenorphine extendedrelease (Sublocade), greater than 100 mg
Q9995 Injection, emicizumab-kxwh, 0.5 mg

 

Disclaimer: Every reasonable effort was made to ensure the accuracy of this information at the time it was published. However, due to the nature of industry changes over time we cannot guarantee its validity after the year it was published.